On December 19, 2025, US President Donald Trump announced landmark agreements with nine leading pharmaceutical companies to reduce the cost of prescription medicines in the United States. The companies involved include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
Under these deals, participating companies have agreed to lower prices for drugs purchased under Medicaid and for patients paying out of pocket, bringing US prices closer to those in other wealthy nations. The agreements also introduce “most‑favoured‑nation” pricing, ensuring new medicines sold in the US will not be priced higher than in comparable countries.
As part of the initiative, the administration plans to launch TrumpRx.gov in January 2026, an online platform that will allow patients to access discounted drugs directly from manufacturers. The platform targets individuals without insurance or those facing high out-of-pocket costs, offering a more affordable route to essential medications.
Some companies have also pledged additional support. For instance, Bristol Myers Squibb will provide its widely used blood thinner, Eliquis, for free to Medicaid recipients. Others will donate raw materials and emergency medical supplies to a national reserve.
In exchange for these concessions, the pharmaceutical firms receive a three-year exemption from potential new tariffs that had previously been under consideration. The Trump administration describes these agreements as a major step toward tackling the high cost of medicines in the US, which historically remains higher than in most other developed nations.
However, experts have cautioned that while these deals may lower costs for some patients, especially the uninsured or low-income, the majority of Americans with standard health insurance may see limited immediate savings.
This move follows earlier agreements earlier in 2025 with Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk, reflecting a broader strategy by the administration to negotiate drug prices directly with manufacturers rather than imposing strict price controls.
With TrumpRx.gov and these pricing deals, the administration aims to make prescription drugs more affordable and accessible, signaling a major policy push on one of the US’s most pressing healthcare issues.
Also Read: Indian Pharma stocks up 5% after US Biosecure Act